FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling-Reference-Cited by-同舟云学术

FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling

Published:2023-10-31 Issue:5 Volume:17 Page:328-339
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Cheng Haihong¹,Sun Yuxin¹,Yu Xiaopeng²,Zhou Di³,Ding Jun⁴,Wang Shouhua²,Ma Fei²

Affiliation:

1. Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

2. Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

3. Department of Hepatobiliary Surgery, Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.

4. Department of Biliary and Pancreatic Surgery, Shanghai Shuguang Hospital Affiliated with the Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.jstage.jst.go.jp/article/ddt/17/5/17_2023.01036/_pdf

Reference39 articles.

1. 1. Koppatz H, Takala S, Peltola K, But A, Makisalo H, Nordin A, Sallinen V. Gallbladder cancer epidemiology, treatment and survival in Southern Finland – a population-based study. Scand J Gastroenterol. 2021; 56:929-939.

2. 2. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba, II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001; 51:349-364.

3. 3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209-249.

4. 4. Rakic M, Patrlj L, Kopljar M, Klicek R, Kolovrat M, Loncar B, Busic Z. Gallbladder cancer. Hepatobiliary Surg Nutr. 2014; 3:221-226.

5. 5. Park K, Kim KP, Park S, Chang HM. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol. 2017; 13:13-20.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CircEZH2 promotes gallbladder cancer progression and lipid metabolism reprogramming through the miR-556-5p/SCD1 axis;iScience;2024-08

2. Acylcarnitines promote gallbladder cancer metastasis through lncBCL2L11-THOC5-JNK axis;Journal of Translational Medicine;2024-03-22

3. New trends in diagnosis and management of gallbladder carcinoma;World Journal of Gastrointestinal Oncology;2024-01-15